LH - Laboratory Corporation of America Holdings
After hours:
| Previous close | 213.37 |
| Open | 213.97 |
| Bid | 210.75 x 800 |
| Ask | 220.31 x 800 |
| Day's range | 212.86 - 215.85 |
| 52-week range | 200.32 - 263.13 |
| Volume | |
| Avg. volume | 581,938 |
| Market cap | 19.102B |
| Beta (5Y monthly) | 1.04 |
| PE ratio (TTM) | 19.39 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 2.88 (1.35%) |
| Ex-dividend date | 17 May 2023 |
| 1y target est | N/A |
- Business Wire
Ovia HealthTM Expands Digital Platform Capabilities to Include Menopause Tracking
BOSTON, February 22, 2023--Ovia Health, a trusted digital health platform for women and families, today announced the expansion of its Ovia® app, which will now allow women to track menopause symptoms and access valuable resources and support to address the transition to menopause/perimenopause. The technology is available through Ovia’s consumer application and enterprise offerings for employers and health plans.
- Business Wire
Labcorp Announces 2022 Fourth Quarter and Full-Year Results
BURLINGTON, N.C., February 16, 2023--Labcorp (NYSE: LH), a leading global life sciences company, today announced results for the fourth quarter and year ended Dec. 31, 2022, full-year 2023 guidance.
- Business Wire
Labcorp Unveils New Name for Future Independent Clinical Development Business - Fortrea
BURLINGTON, N.C., February 09, 2023--Labcorp (NYSE: LH), a leading global life sciences company, today announced that the new company to be formed by the planned spin-off of its Clinical Development business will be known as Fortrea. Upon completion of the spin-off from Labcorp, Fortrea will operate as an independent, publicly traded global CRO that offers comprehensive drug and medical device development services. With over 19,000 people, Fortrea will provide Phase I through IV clinical trial m
- Business Wire
Labcorp to Announce Fourth Quarter and Full Year 2022 Financial Results on February 16, 2023
BURLINGTON, N.C., January 18, 2023--Labcorp (NYSE: LH), a leading global life sciences company, will release its financial results for the fourth quarter and full year 2022 before the market opens on Thursday, Feb. 16, 2023. The company will host a conference call and webcast beginning at 9 a.m. ET that day to discuss the results. The earnings press release and accompanying financial information will be posted on the Labcorp Investor Relations website.
- Business Wire
Labcorp Declares Quarterly Dividend
BURLINGTON, N.C., January 12, 2023--Labcorp (NYSE: LH), a leading global life sciences company, announced today that its Board of Directors has declared a cash dividend of $0.72 per share of common stock. The dividend will be payable on March 13, 2023, to stockholders of record as of the close of business on Feb. 23, 2023.
- Business Wire
Thomas Pike to Join Labcorp as President and Chief Executive Officer of Its Drug Development Clinical Development Business Unit
BURLINGTON, N.C., January 05, 2023--Labcorp (NYSE: LH), a leading global life sciences company, today announced that Thomas (Tom) Pike will join Labcorp as president and chief executive officer of its Drug Development Clinical Development business unit on Jan. 9, 2023. Until the planned spin-off of the Clinical Development business, which is expected to occur in mid-2023, Mr. Pike will report to Labcorp’s chairman and CEO Adam Schechter. At the time of the spin-off, Mr. Pike will serve as the ch
- Business Wire
Labcorp to Speak at the 41st Annual J.P. Morgan Healthcare Conference
BURLINGTON, N.C., January 03, 2023--Labcorp (NYSE: LH), a leading global life sciences company, today announced that members of the executive management team will participate in a fireside chat at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, Jan. 10 at 4:30 p.m. (PT).
- Business Wire
Labcorp Opens New Los Angeles Based Laboratory
BURLINGTON, N.C., December 08, 2022--Labcorp (NYSE: LH), a leading global life sciences company, today announced that it has begun operations at a new, larger anatomic pathology and histology (APH) laboratory in Los Angeles, expanding the company’s global central laboratory capabilities.
- Business Wire
Labcorp to Speak at the Credit Suisse 31st Annual Healthcare Conference
BURLINGTON, N.C., October 31, 2022--Labcorp (NYSE: LH), a leading global life sciences company, today announced that members of the executive management team will participate in a fireside chat at the Credit Suisse 31st Annual Healthcare Conference on Tuesday, Nov. 8, at 1:25 p.m. PT.
- Business Wire
Labcorp Announces 2022 Third Quarter Results
BURLINGTON, N.C., October 27, 2022--Labcorp (NYSE: LH), a leading global life sciences company, today announced results for the third quarter ended Sept. 30, 2022, and updated full-year guidance.
- Business Wire
Labcorp Appoints Google Cloud Executive Kirsten Kliphouse to Its Board of Directors
BURLINGTON, N.C., October 13, 2022--Labcorp (NYSE: LH), a leading global life sciences company, today announced that Kirsten Kliphouse, president of Americas, Google Cloud, has joined its Board of Directors as an independent member.
- Business Wire
Labcorp Establishes Comprehensive Laboratory Relationship With Ascension
BURLINGTON, N.C., October 03, 2022--Labcorp (NYSE: LH), a leading global life sciences company, today announced the completion of transactions that establish a long-term laboratory relationship with Ascension, one of the leading non-profit and Catholic health systems in the United States.
- Business Wire
Labcorp to Announce Third Quarter Financial Results on October 27, 2022
BURLINGTON, N.C., September 27, 2022--Labcorp (NYSE: LH), a leading global life sciences company, will release its financial results for the third quarter of 2022 before the market opens on Thursday, Oct. 27, 2022. The company will host a conference call and webcast beginning at 9 a.m. ET that day to discuss the results. The earnings press release and accompanying financial information will be posted on the Labcorp Investor Relations website.
- Business Wire
Labcorp to Speak at the Baird 2022 Global Healthcare Conference
BURLINGTON, N.C., September 06, 2022--Labcorp (NYSE: LH), a leading global life sciences company, today announced that members of the executive management team will participate in a fireside chat at the Baird 2022 Global Healthcare Conference on Tuesday, Sept. 13, at 9:05 a.m. ET.
- Business Wire
Labcorp Acquires Clinical Outreach Laboratory Services From RWJBarnabas Health
BURLINGTON, N.C., August 23, 2022--Labcorp (NYSE: LH), a leading global life sciences company, today announced that it has closed its acquisition of RWJBarnabas Health’s outreach laboratory business and select related assets. RWJBarnabas Health is New Jersey’s largest academic health system.
- Business Wire
Labcorp Announces 2022 Second Quarter Results
BURLINGTON, N.C., July 28, 2022--Labcorp (NYSE: LH), a leading global life sciences company, today announced results for the second quarter ended June 30, 2022, and updated full-year guidance.
- Business Wire
Labcorp to Spin Off Clinical Development Business
BURLINGTON, N.C., July 28, 2022--Labcorp (NYSE: LH) (the "Company"), a leading global life sciences company, today announced that its Board of Directors has authorized the Company to pursue a spin-off of the Company’s wholly owned Clinical Development business to Labcorp shareholders through a tax-free transaction. The planned spin-off will result in two independent, publicly traded companies, each poised for strong, sustainable growth:
- Business Wire
Labcorp Earns Top Score on 2022 Disability Equality Index
BURLINGTON, N.C., July 22, 2022--Labcorp (NYSE: LH), a leading global life sciences company, today announced that it scored 100, the highest score possible, on the 2022 Disability Equality Index® (DEI), a comprehensive benchmarking tool for measuring disability inclusion in the workplace. The DEI, a joint initiative by Disability:IN® and the American Association of People with Disabilities (AAPD), exists to help businesses make a positive impact on the unemployment and underemployment of people
- Business Wire
New Labcorp Test Report Helps Identify Insect Stings and Improve Therapy Decisions to Combat Allergic Reactions
BURLINGTON, N.C., July 19, 2022--Nearly 10 million people in the United States have a history of systemic or anaphylactic reaction to insect stings, with the risk of a severe and potentially life-threatening allergic reaction. To help facilitate more effective venom therapy, Labcorp (NYSE: LH), a leading global life sciences company, has launched its unique Labcorp Clinical Decision Support (CDS) interpretative test report for its Stinging Insect Component-Specific IgE Test that provides allerge
- Business Wire
Labcorp Expands Automated Clinical Trial Kit Production Line at European Operations Center
BURLINGTON, N.C., July 18, 2022--Labcorp® (NYSE: LH), a leading global life sciences company, today announced an expansion of its automated clinical trial kit production line in Mechelen, Belgium. Once completed, expansion will allow for clinical trial test kits to be fulfilled in Mechelen for more than 70 countries throughout Europe, the Middle East and Africa (EMEA). This is up from 27 countries in 2021. The company’s industry-leading central laboratory services unit is part of Labcorp Drug De
- Business Wire
Labcorp to Announce Second Quarter Financial Results on July 28, 2022
BURLINGTON, N.C., July 14, 2022--Labcorp (NYSE: LH), a leading global life sciences company, will release its financial results for the second quarter of 2022 before the market opens on Thursday, July 28, 2022. The company will host a conference call and webcast beginning at 9 a.m. EDT that day to discuss the results. The earnings press release and accompanying financial information will be posted on the Labcorp Investor Relations website.
- Business Wire
Labcorp Launches New Test to Identify and Confirm Neurodegenerative Disease
BURLINGTON, N.C., July 13, 2022--Labcorp (NYSE: LH), a leading global life sciences company, today announced the launch of the first widely accessible test that provides direct evidence of neurodegeneration and neuronal injury. The new Neurofilament Light Chain (NfL) blood test will allow doctors to identify and verify signs of neurodegenerative disease, enabling physicians to provide a more effective and efficient path to diagnosis and treatment for patients. Elevated NfL levels signal neuronal
- Business Wire
Labcorp Forms Strategic Partnership With MD Anderson Cancer Center Foundation Spain to Increase Access to Early Phase Oncology Clinical Trials
BURLINGTON, N.C., July 11, 2022--Labcorp (NYSE: LH), a leading global life sciences company, today announced it has formed a strategic partnership with MD Anderson Cancer Center Foundation Spain, a non-profit organization whose objectives are to beat cancer and to increase accessibility of early phase oncology clinical trials. Through this collaboration, oncology clinical trials managed by Labcorp Drug Development will be prioritized and conducted at MD Anderson Cancer Center Foundation Spain, r
- Business Wire
Labcorp First National Laboratory to Offer Monkeypox Test
BURLINGTON, N.C., July 06, 2022--Labcorp (NYSE: LH), a leading global life sciences company, today announced it will begin testing for monkeypox using the U.S. Centers for Disease Control and Prevention’s (CDC) orthopoxvirus test, which detects all non-smallpox related orthopoxviruses, including monkeypox. This effort is part of the Administration’s commitment to quickly increase monkeypox testing access and capacity in every community during the ongoing outbreak.
- Business Wire
Labcorp Plans Laboratory Expansion in Japan Through BML Collaboration
BURLINGTON, N.C., June 28, 2022--Labcorp (NYSE: LH), a leading global life sciences company, today announced that it is enhancing its central laboratory presence and drug development capabilities in Japan through an expansion of CB Trial Laboratory, the central laboratory co-managed by Labcorp Drug Development and BML, a leading Japanese provider of clinical laboratory testing services.
